Eight Senators Ask the DEA to Restore a Proposed Cap and Reapply a Ban It Has Not Removed
Eight senators are urging the Drug Enforcement Administration (DEA) to revive a cap it once floated but never enforced, and to reimpose a prohibition on a substance it already bans. Their letter presses the agency to undo changes it has only proposed so far.
Kratom is described as having opioid-like qualities, since certain kratom compounds activate the same receptor that morphine does. Yet this does not mean all kratom products are identical. Kratom leaves hold tiny amounts of 7-hydroxymitragynine (7-OH), but a cup of kratom tea can deliver a vastly different dose than a tablet containing a concentrated amount of 7-OH. The senators’ shorthand overlooks a distinction that matters when the government is deciding what should be illegal.
A new analysis from the Reason Foundation, the nonprofit that publishes Reason, notes that people have long used kratom to manage pain and to cope with opioid withdrawal. In a survey, users reported turning to kratom for anxiety, for pain relief while avoiding conventional opioids, or to reduce or stop using other opioids. In a letter to the Department of Health and Human Services, nine military veterans described using concentrated 7-OH to treat pain and symptoms of post-traumatic stress disorder and to move away from other opioids or alcohol. These accounts illustrate why individuals seek out these products. Whether the products reliably help them remains an open question for researchers.
In July, the DEA proposed placing 7-OH in Schedule I, a federal classification that typically makes possession a crime, if the compound makes up more than 0.05 percent of a product by weight. That proposal never took effect. In August, the agency issued an order placing a related compound, mitragynine pseudoindoxyl (MP), in Schedule I regardless of its concentration.
On October 14, the DEA proposed new limits. Under the plan, solid products containing more than 0.1 percent 7-OH or MP by weight would fall under Schedule I, with the two compounds counted together if both are present. The proposal also sets a separate concentration limit for liquids. It further requires that natural kratom’s main active ingredient, mitragynine, be present at least 100 parts for every part of 7-OH and MP combined. A product may fall below the concentration limit and still be subject to Schedule I controls if it fails that secondary test.
The DEA said it would issue an order implementing the limits on or after November 13, which was the earliest feasible date. The limits did not automatically take effect on that date, and the August order placing MP in Schedule I remained in place. By November 19, the agency had not issued an order to activate the new limits.
In a November 16 letter to the DEA and the Food and Drug Administration (FDA), Sen. Charles Grassley (R–Iowa) and seven colleagues argued that the agency had effectively doubled the previously permissible concentration of 7-OH and had removed MP from Schedule I. The senators correctly noted that for solids, 0.1 percent is twice 0.05 percent. However, the July and October figures derive from proposals, and the October plan would keep MP under Schedule I controls in products that exceed either threshold. It is reasonable to ask the FDA to explain why health officials supported raising the cutoff, but insisting that the DEA reimpose a ban it has not removed crosses a different line altogether.
A concentration cap tells us surprisingly little about the actual dose someone consumes. Two tablets of different sizes could contain the same quantity of 7-OH, even if one tablet surpasses the limit and the other does not. The DEA has acknowledged that controlled human trials have not yet established safe consumption levels for concentrated 7-OH. What evidence would demonstrate that the senators’ preferred cutoff actually enhances consumer safety? What data would justify prosecuting adults for possessing a product that falls beyond that threshold?
Under federal law, Schedule I is reserved for substances deemed to have a high potential for abuse and no accepted medical use in the United States, among other criteria. Congress also granted the DEA authority to place substances there temporarily if there is an imminent threat to public safety. The thresholds were suggested by health officials, but the DEA decides whether to implement them. Federal drug policing already determines what adults may use to manage pain or cope with withdrawal. Now eight senators want to determine that for the public, down to the smallest fraction.
Both potency and dependence deserve consideration. Adults deserve clear information about what they are buying, including the amounts of each compound a product contains and the risks involved. Proper labeling, independent testing, and enforcement against fraud can help. A ban can alter where people shop and what they purchase. Some individuals who rely on 7-OH for pain relief or withdrawal management might turn to illicit sellers or switch to more dangerous substances. The senators should also ask the agencies to consider those risks.
The eight senators are seeking answers from the FDA and the DEA by November 30. They ask what people living with pain or trying to reduce or quit other opioids should do if the products they depend on disappear. It is troubling enough that we allow law enforcement to influence medical decisions; do we really want eight lawmakers determining prescriptions down to the decimal point?